Children and adolescents are at a significantly higher risk of various SARS-CoV-2 infection (PASC/long COVID) outcomes after reinfection with SARS-CoV-2, researchers reported in Lancet Infectious Diseases on September… read more.
Novavax Inc. announced a milestone payment from Takeda has been triggered by regulatory approval in Japan for Novavax’s Covid-19 vaccine Nuvaxovid 2025-2026 Formula (Intramuscular Injection 1 mL) formulated… read more.
A lack of soap is the most often reported barrier to effective hand hygiene—key to curbing the spread of infection—in shared community spaces, such as households, schools, and… read more.
Moderna Inc. announced that the FDA has approved the supplemental Biologics License Applications (sBLA) for the 2025-2026 formulas for Spikevax and mNEXSPIKE, targeting the LP.8.1 variant of SARS-CoV-2… read more.
Novavax, Inc. announced that the FDA has approved the Nuvaxovid 2025-2026 Formula for the prevention of COVID-19 in individuals 65 years of age and older, or 12 years… read more.
Shionogi & Co., Ltd. announced the FDA has accepted for review a New Drug Application (NDA) from Shionogi Inc., its US subsidiary for ensitrelvir (Xocova, enensitrelvir fumaric acid,… read more.
Gilead Sciences Inc. announced that the European Commission (EC) has granted marketing authorization for Yeytuo (lenacapavir)—the company’s twice-yearly injectable HIV-1 capsid inhibitor—for use as pre-exposure prophylaxis (PrEP) to… read more.
The human papillomavirus (HPV) can cause six types of cancer. It’s responsible for almost all cervical cancer cases. HPV now causes the majority of oropharyngeal (throat) cancers. It… read more.
Researchers at Arizona State University have developed a breakthrough diagnostic tool that could transform how quickly and reliably we detect illnesses like COVID-19, Ebola, AIDS or Lyme disease…. read more.
The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending a change to the terms of the marketing authorisation for Xofluza. The marketing authorisation… read more.
Merck Inc. announced that the Committee for Medicinal Products for Human Use (CHMP) of the EMA recommended the approval of Capvaxive (Pneumococcal 21-valent Conjugate Vaccine) for active immunization… read more.
Ivermectin administered to the whole population significantly reduces malaria transmission, offering new hope in the fight against the disease. The BOHEMIA trial, the largest study on ivermectin for malaria… read more.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
